- Home
- SNTI vs IMAB Comparison
SNTI vs IMAB Comparison
Compare SNTI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IMAB
- Stock Information
- Founded
- SNTI 2016
- IMAB 2014
- Country
- SNTI United States
- IMAB United States
- Employees
- SNTI N/A
- IMAB N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- IMAB Health Care
- Exchange
- SNTI Nasdaq
- IMAB Nasdaq
- Market Cap
- SNTI 85.3M
- IMAB 73.9M
- IPO Year
- SNTI N/A
- IMAB 2020
- Fundamental
- Price
- SNTI $3.56
- IMAB $2.29
- Analyst Decision
- SNTI Strong Buy
- IMAB Strong Buy
- Analyst Count
- SNTI 1
- IMAB 2
- Target Price
- SNTI $12.00
- IMAB $5.50
- AVG Volume (30 Days)
- SNTI 25.9K
- IMAB 635.7K
- Earning Date
- SNTI 05-06-2025
- IMAB 05-15-2025
- Dividend Yield
- SNTI N/A
- IMAB N/A
- EPS Growth
- SNTI N/A
- IMAB N/A
- EPS
- SNTI N/A
- IMAB N/A
- Revenue
- SNTI N/A
- IMAB N/A
- Revenue This Year
- SNTI N/A
- IMAB N/A
- Revenue Next Year
- SNTI N/A
- IMAB N/A
- P/E Ratio
- SNTI N/A
- IMAB N/A
- Revenue Growth
- SNTI N/A
- IMAB N/A
- 52 Week Low
- SNTI $1.52
- IMAB $0.60
- 52 Week High
- SNTI $16.94
- IMAB $2.68
- Technical
- Relative Strength Index (RSI)
- SNTI 58.08
- IMAB 86.59
- Support Level
- SNTI $3.04
- IMAB $1.20
- Resistance Level
- SNTI $3.25
- IMAB $1.47
- Average True Range (ATR)
- SNTI 0.23
- IMAB 0.22
- MACD
- SNTI 0.04
- IMAB 0.12
- Stochastic Oscillator
- SNTI 89.83
- IMAB 78.59
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).